Clinical impact of selumetinib on pediatric elephantiasis neuromatosa

Elephantiasis neuromatosa (EN) is a rare and extreme form of plexiform neurofibroma in patients with neurofibromatosis type 1 (NF1). EN is often associated with significant morbidity and remains difficult to treat. We present a case of an 11‐year‐old female with NF1 whose thoracolumbar plexiform neu...

Descripción completa

Detalles Bibliográficos
Autores principales: Blegen, Kristina, Ortiz‐Romero, Sara E., Juarez, Olivia, Voeller, Julie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796138/
https://www.ncbi.nlm.nih.gov/pubmed/35739628
http://dx.doi.org/10.1111/pde.15044
_version_ 1784860415383044096
author Blegen, Kristina
Ortiz‐Romero, Sara E.
Juarez, Olivia
Voeller, Julie
author_facet Blegen, Kristina
Ortiz‐Romero, Sara E.
Juarez, Olivia
Voeller, Julie
author_sort Blegen, Kristina
collection PubMed
description Elephantiasis neuromatosa (EN) is a rare and extreme form of plexiform neurofibroma in patients with neurofibromatosis type 1 (NF1). EN is often associated with significant morbidity and remains difficult to treat. We present a case of an 11‐year‐old female with NF1 whose thoracolumbar plexiform neurofibroma and lower extremity EN exhibited clinical improvement from treatment with selumetinib, a selective MEK inhibitor.
format Online
Article
Text
id pubmed-9796138
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97961382022-12-30 Clinical impact of selumetinib on pediatric elephantiasis neuromatosa Blegen, Kristina Ortiz‐Romero, Sara E. Juarez, Olivia Voeller, Julie Pediatr Dermatol Case Reports Elephantiasis neuromatosa (EN) is a rare and extreme form of plexiform neurofibroma in patients with neurofibromatosis type 1 (NF1). EN is often associated with significant morbidity and remains difficult to treat. We present a case of an 11‐year‐old female with NF1 whose thoracolumbar plexiform neurofibroma and lower extremity EN exhibited clinical improvement from treatment with selumetinib, a selective MEK inhibitor. John Wiley and Sons Inc. 2022-06-23 2022 /pmc/articles/PMC9796138/ /pubmed/35739628 http://dx.doi.org/10.1111/pde.15044 Text en © 2022 The Authors. Pediatric Dermatology published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Blegen, Kristina
Ortiz‐Romero, Sara E.
Juarez, Olivia
Voeller, Julie
Clinical impact of selumetinib on pediatric elephantiasis neuromatosa
title Clinical impact of selumetinib on pediatric elephantiasis neuromatosa
title_full Clinical impact of selumetinib on pediatric elephantiasis neuromatosa
title_fullStr Clinical impact of selumetinib on pediatric elephantiasis neuromatosa
title_full_unstemmed Clinical impact of selumetinib on pediatric elephantiasis neuromatosa
title_short Clinical impact of selumetinib on pediatric elephantiasis neuromatosa
title_sort clinical impact of selumetinib on pediatric elephantiasis neuromatosa
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796138/
https://www.ncbi.nlm.nih.gov/pubmed/35739628
http://dx.doi.org/10.1111/pde.15044
work_keys_str_mv AT blegenkristina clinicalimpactofselumetinibonpediatricelephantiasisneuromatosa
AT ortizromerosarae clinicalimpactofselumetinibonpediatricelephantiasisneuromatosa
AT juarezolivia clinicalimpactofselumetinibonpediatricelephantiasisneuromatosa
AT voellerjulie clinicalimpactofselumetinibonpediatricelephantiasisneuromatosa

Ejemplares similares